Business
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been recognized for excellence across multiple categories for "Large CDMO Biologic", including "Best Scaling Support", "Best Analytical Services", "Best Overall Staff", and "Best Project Management". These achievements mark WuXi Biologics' ninth c
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"text","content":"SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been recognized for excellence across multiple categories for "Large CDMO Biologic", including "Best Scaling Support", "Best Analytical Services", "Best Overall Staff", and "Best Project Management". These achievements mark WuXi Biologics' ninth consecutive year winning the CDMO Leadership Awards, underscoring its commitment to advancing integrated technology platforms that accelerate biologics discovery, development, and manufacturing.","length":813,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/ce4879920f1eb2e74898a881e82da5bb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eFFIMH7QMln6RsF4sAcSlg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU2MA--/https://media.zenfs.com/en/prnewswire.com/ce4879920f1eb2e74898a881e82da5bb","width":300,"height":400}},"href":"https://mma.prnewswire.com/media/2945253/image.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are honored to receive the CDMO Leadership Award for the ninth consecutive year. This recognition reflects the continued trust of our global partners and the dedication of our more than 13,000 employees worldwide. By advancing integrated technology platforms, manufacturing excellence, and digital innovation, we remain committed to helping our partners accelerate development, ensure quality and scalability, and bring life‑saving biologics to patients worldwide."","length":534,"tagName":"p"},{"type":"text","content":"As of the end of 2025, WuXi Biologics has 945 integrated projects on its platform, making it one of the world's largest portfolios of complex biologics. Among them, more than 50% are complex modalities, such as bi-/multi-specific antibodies and ADCs. Supported by innovative technology platforms, deep accumulated know‑how in molecule and proce...